A renaissance for SRC
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that SRC activation may also be a dominant feature in CRC, which is supported by the observation that SRC activation was documented in > 80% of CRC [17].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“In response signaling from a variety of RTKs (including EGFR, HER2, HER4, PDGFR, VEGFR, FGFR4, GPCR, C-MET, IL-4/IL13/IL-13Rα2, IL-6ST/IL-6R/IL-11R), SRC has been reported to mediate diverse cell signaling pathways including RAS/MAPK (proliferation), PI3K/AKT (survival), FAK (adhesion/migration/EMT), and STAT3 (angiogenesis) [17, 49, 50].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“Aberrant SRC activation has been associated with a more aggressive phenotype and a worse prognosis in CRC patients [27, 28, 39].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [39]
In the citing paper
“The c-src is a non-receptor protein tyrosine kinase with a 60-kD molecular weight.It is a member of a 9-gene family named the Src family kinases (SFKs)”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [1]
Citations
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859 · cited 1×
“Focal adhesions are also disassembled during transformation, during which the integrity of these structures is disrupted, permitting increased motilit”
BackgroundCell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915 · cited 1×
“This is followed by release of adhesions and retraction of the rear en”
BackgroundGiancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345 · cited 1×
“Although not yet reported for c- SRC , it has been possible to transform human fibroblasts with oncogenes such as HRAS when they are combined with human telomerase reverse transcriptase and the SV40 large T antige”
BackgroundTransforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332 · cited 1×
“v- src was subsequently shown to encode a tyrosine-specific protein kinas”
BackgroundThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STAT3 activation by v-Src has also been shown to contribute to other biological properties of cancer cells, including cell growth and survival, and tumour-cell immune evasio”
BackgroundFOCAL ADHESIONS, CONTRACTILITY, AND SIGNALING
Burridge, K., & Chrzanowska-Wodnicka, M. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.463 · Cited by 1,942 · cited 1×
“Small adhesions can transmit stong forces for rapid movement and ultimately mature into larger focal adhesion”
BackgroundReduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice
llić, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., et al. (1995) · Nature · doi:10.1038/377539a0 · Cited by 1,830
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.
Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D., & Birchmeier, W. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.1.173 · Cited by 1,551 · cited 1×
“Definitive studies in transgenic mice indicate that E-cadherin is an invasion suppresso”
BackgroundA causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,424 · cited 1×
“and overexpression of E-cadherin can, in fact, counteract the acquisition of the invasive phenotyp”
Background
Cited by
Molecular requirements for epithelial–mesenchymal transition during tumor progression
Huber, M. A., Kraut, N., & Beug, H. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.08.001 · Cited by 1,821
The Blood-Testis Barrier and Its Implications for Male Contraception
Cheng, C. Y., & Mruk, D. D. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.002790 · Cited by 927
“Of these, c-Src is the best studied Src kinase family member, and since being discovered y by Francis Peyton Rous in 1911, it has been implicated in oncogenesis (Martin, 2001, 2009; Yeatman, 2004; Aleshin and Finn, 2010) (Fig.”
BackgroundThe Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
The LIR motif – crucial for selective autophagy
Birgisdottir, Å. B., Lamark, T., & Johansen, T. (2013) · Journal of Cell Science · doi:10.1242/jcs.126128 · Cited by 885
“Increased Src activity promotes tumorigenesis but excessive Src signaling can be cytotoxic (Yeatman, 2004).”
BackgroundSmall-molecule–induced DNA damage identifies alternative DNA structures in human genes
Rodriguez, R., Miller, K. M., Forment, J. V., Bradshaw, C. R., Nikan, M., Britton, S., Oelschlaegel, T., Xhemalce, B., Balasubramanian, S., & Jackson, S. P. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.780 · Cited by 741
“SRC is a nonreceptor tyrosine kinase that has crucial roles in various cellular processes, including cell motility and invasio”
Src kinases as therapeutic targets for cancer
Kim, L. C., Song, L., & Haura, E. B. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.129 · Cited by 700
“The nine members of the Src-family kinases (SFKs) are c-Src, Yes, Fyn, Lyn, Lck, Hck, Fgr, Blk, and Yrk”
BackgroundSrc kinase regulation by phosphorylation and dephosphorylation
Roskoski, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.012 · Cited by 577
Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion
Narumiya, S., Tanji, M., & Ishizaki, T. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9170-7 · Cited by 530
“v-Src is the oldest oncogene, and its proto-oncogene, c-Src, is amplified in a variety of clinical cancers and its activity often correlates with their invasive potency [75].”
BackgroundReceptor-Like Cytoplasmic Kinases: Central Players in Plant Receptor Kinase–Mediated Signaling
Liang, X., & Zhou, J.-M. (2018) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-042817-040540 · Cited by 500
EGFR Signaling and Drug Discovery
Lurje, G., & Lenz, H.-J. (2009) · Oncology · doi:10.1159/000279388 · Cited by 442
Lyn is a redox sensor that mediates leukocyte wound attraction in vivo
Yoo, S. K., Starnes, T. W., Deng, Q., & Huttenlocher, A. (2011) · Nature · doi:10.1038/nature10632 · Cited by 442
“SFKs maintain inhibitory intramolecular interactions in an inactive state, while dephosphorylation of the C-terminal phosphotyrosine releases the inhibitory configuration, allowing trans-autophosphorylation of the activation loop tyrosine, thereby activating SFKs 20–23 .”
Wang, Z. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7219-7_1 · Cited by 430
Src signaling in cancer invasion
Guarino, M. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22011 · Cited by 426
“(7) The C-terminal tail containing the negative-regulatory Tyr530 (in humans) that, when phosphorylated, can dock to the SH2 domain (Roskoski, 2004; Yeatman, 2004).”
BackgroundInfluentialAction of the Src Family Kinase Inhibitor, Dasatinib (BMS-354825), on Human Prostate Cancer Cells
Nam, S., Kim, D., Cheng, J. Q., Zhang, S., Lee, J.-H., Buettner, R., Mirosevich, J., Lee, F. Y., & Jove, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1731 · Cited by 377
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
“…as an oncogene in animal models 316 several decades ago, the evidence of mutation or overexpression of Src family kinases in human prostate cancer is scant, while it has been shown that Src kinase is overexpressed in breast and colon cancer patients (Biscardi et al., 2000; Yeatman, 2004).”
Johnson, F. M., Saigal, B., Talpaz, M., & Donato, N. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0757 · Cited by 333
Regulation of the Src Family Kinases by Csk
Okada, M. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.5141 · Cited by 309
“Dysregulation of SFKs has been implicated in the etiology of various human diseases such as cancers, although somatic mutation in the SFK genes has not been detected [12, 13].”
BackgroundTargeting Src family kinases in anti-cancer therapies: turning promise into triumph
Zhang, S., & Yu, D. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.11.002 · Cited by 319
“The roles of Src in tumor progression and metastasis have been well-documented [1].”
BackgroundInfluentialDrosophila melanogaster: A Model Organism to Study Cancer
Mirzoyan, Z., Sollazzo, M., Allocca, M., Valenza, A. M., Grifoni, D., & Bellosta, P. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00051 · Cited by 317
Aiding and abetting roles of NOX oxidases in cellular transformation
Block, K., & Gorin, Y. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3339 · Cited by 297
Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells
Nam, S., Buettner, R., Turkson, J., Kim, D., Cheng, J. Q., Muehlbeyer, S., Hippe, F., Vatter, S., Merz, K.-H., Eisenbrand, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409467102 · Cited by 294
Mehrotra, S., Languino, L. R., Raskett, C. M., Mercurio, A. M., Dohi, T., & Altieri, D. C. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.021 · Cited by 291
“…the extracellular matrix, fibronectin binds multiple integrins (Cukierman et al., 2002), resulting in the activation of focal adhesion kinase (FAK) (Sieg et al., 2000), Src (Yeatman, 2004), and Akt (Irie et al., 2005), as well as modulation of small GTPases of the Rho family (Nobes and Hall, 1995).”
BackgroundValeri, N., Braconi, C., Gasparini, P., Murgia, C., Lampis, A., Paulus-Hock, V., Hart, J. R., Ueno, L., Grivennikov, S. I., Lovat, F., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.006 · Cited by 286
“SRC is nonmembrane receptor tyrosine kinase (Yeatman 2004) and induces activation of several pathways.”
Structure and mechanisms of ROS generation by NADPH oxidases
Magnani, F., & Mattevi, A. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.03.001 · Cited by 279
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Li, J., Rix, U., Fang, B., Bai, Y., Edwards, A., Colinge, J., Bennett, K. L., Gao, J., Song, L., Eschrich, S., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.332 · Cited by 283
“SFK form a closely related family of non-receptor tyrosine kinases (reviewed in (8) ) that link signaling from distinct upstream cell surface receptors to downstream effector pathways.”
BackgroundInfluentialPROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283
Hiscox, S., Morgan, L., Green, T. P., Barrow, D., Gee, J., & Nicholson, R. I. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9120-9 · Cited by 274
“Elevated Src activity has been implicated in promoting an aggressive tumour cell phenotype and thus Src presents itself as a potential therapeutic target for the prevention of tumour spread [22,28].”
BackgroundWei, Y., Jiang, Y., Zou, F., Liu, Y., Wang, S., Xu, N., Xu, W., Cui, C., Xing, Y., Liu, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217002110 · Cited by 274
“The Src family kinases are nonreceptor tyrosine kinases that are activated rapidly on the engagement of multiple cell surface receptors and modulate several cellular processes, including proliferation, adhesion, migration, and differentiation (42, 43).”
BackgroundNew targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
Rainey, M. D., Charlton, M. E., Stanton, R. V., & Kastan, M. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0763 · Cited by 266
“These compounds were screened using an in vitro ELISA assay, with potential inhibitors being identified by a decreased ability of purified ATM kinase to phosphorylate GST-p53(1-101) substrate (data not shown).”
InfluentialDirect regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404848111 · Cited by 269
“Although SRC plays a central role in mediating multiple protumorigenic signaling cascades, it is rarely mutated in cancers (32).”
BackgroundVennin, C., Chin, V. T., Warren, S. C., Lucas, M. C., Herrmann, D., Magenau, A., Melenec, P., Walters, S. N., del Monte-Nieto, G., Conway, J. R. W., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8504 · Cited by 267
Vaults and the major vault protein: Novel roles in signal pathway regulation and immunity
Berger, W., Steiner, E., Grusch, M., Elbling, L., & Micksche, M. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8364-z · Cited by 253
Yamaguchi, T., Yanagisawa, K., Sugiyama, R., Hosono, Y., Shimada, Y., Arima, C., Kato, S., Tomida, S., Suzuki, M., Osada, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.008 · Cited by 249
Targeting Src in breast cancer
Finn, R. S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn291 · Cited by 248
“Other SFK members include Lyn, Fyn, Lck, Hck, Fgr, Blk, Yrk, and Yes [8, 9].”
BackgroundInfluentialLocation, location, location: new insights into O-GalNAc protein glycosylation
Gill, D. J., Clausen, H., & Bard, F. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.11.004 · Cited by 246
Carretero, J., Shimamura, T., Rikova, K., Jackson, A. L., Wilkerson, M. D., Borgman, C. L., Buttarazzi, M. S., Sanofsky, B. A., McNamara, K. L., Brandstetter, K. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.026 · Cited by 243
“SRC and FAK activation results in focal adhesion disassembly and turnover, through downregulation of RhoA, resulting in increased cellular motility (Arthur et al., 2000; Yeatman, 2004).”
BackgroundInfluentialTargeting JAK kinase in solid tumors: emerging opportunities and challenges
Buchert, M., Burns, C. J., & Ernst, M. (2016) · Oncogene · doi:10.1038/onc.2015.150 · Cited by 243
Current Therapeutic Strategies and Novel Approaches in Osteosarcoma
Ando, K., Heymann, M.-F., Stresing, V., Mori, K., Rédini, F., & Heymann, D. (2013) · Cancers · doi:10.3390/cancers5020591 · Cited by 234
“Src activates tumor cell-motility and invasion [125].”
Shor, A. C., Keschman, E. A., Lee, F. Y., Muro-Cacho, C., Letson, G. D., Trent, J. C., Pledger, W. J., & Jove, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3469 · Cited by 234
“In the specific case of Iressa, EGFR mutations have been shown to influence response to Iressa; however, mutations in the c-Src gene are extremely rare in human cancers (41).”
BackgroundRegulation of Src Family Kinases in Human Cancers
Sen, B., & Johnson, F. M. (2011) · Journal of Signal Transduction · doi:10.1155/2011/865819 · Cited by 228
“Src is a 60-KDa protein composed of several functional domains [13, 17, 18].”
BackgroundPiegeler, T., Votta-Velis, E. G., Liu, G., Place, A. T., Schwartz, D. E., Beck-Schimmer, B., Minshall, R. D., & Borgeat, A. (2012) · Anesthesiology · doi:10.1097/aln.0b013e3182661977 · Cited by 228
“ated with focal adhesions and actin bundling, which control cell membrane protrusions.(38,39) Src is also an upstream regulator of family GTPases such as Rac and , which together”
BackgroundSequential signals toward podosome formation in NIH-src cells
Oikawa, T., Itoh, T., & Takenawa, T. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200801042 · Cited by 228
“The online version of this paper contains supplemental material.”
BackgroundTreatment for Advanced Tumors: Src Reclaims Center Stage
Summy, J. M., & Gallick, G. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2692 · Cited by 225
Wang, Y., & McNiven, M. A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201105153 · Cited by 222
“…FAK–p130Cas–MT1 complex formation and ECM degradation at focal adhesions Src kinase is a central signaling molecule known to promote ECM degradation (Yeatman, 2004; Courtneidge et al., 2005; Kelley et al., 2010) by phosphorylating a variety of substrates including Tyr573 on the cytoplasmic tail…”
InfluentialThe KDEL receptor: New functions for an old protein
Capitani, M., & Sallese, M. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.10.053 · Cited by 220
“SFKs have also been shown to be downstream effectors of GPCRs and tyrosine kinase receptors [61,62].”
BackgroundDasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Finn, R. S., Bengala, C., Ibrahim, N., Roché, H., Sparano, J., Strauss, L. C., Fairchild, J., Sy, O., & Goldstein, L. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0288 · Cited by 220
“SRC is a ubiquitously expressed intracellular tyrosine kinase that regulates protein–protein interactions and signaling pathways involved in adhesion, migration, invasion, protection against apoptosis, and vascular endothelial growth factor expression (12, 13).”
BackgroundRecurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P., Caccese, M., Cerretti, G., Idbaih, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 214
“Proto-oncogene tyrosine-protein kinase Src family (SFK) activation has often been found in patients with GBM associated with greater cell motility and invasion [134]; furthermore, SFK signaling would appear to be upregulated in patients with progressive GBM after bevacizumab therapy [135].”
BackgroundAXL Is a Potential Target for Therapeutic Intervention in Breast Cancer Progression
Zhang, Y.-X., Knyazev, P. G., Cheburkin, Y. V., Sharma, K., Knyazev, Y. P., Őrfi, L., Szabadkai, I., Daub, H., Kéri, G., & Ullrich, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2661 · Cited by 210
SRC: A Century of Science Brought to the Clinic
Aleshin, A., & Finn, R. S. (2010) · Neoplasia · doi:10.1593/neo.10328 · Cited by 211
“Loss of the negative-regulatory C-terminal segment, as occurs in v-Src, has been shown to result in increased activity and transforming potential [1,7].”
BackgroundInfluentialYoo, S. K., Freisinger, C. M., LeBert, D. C., & Huttenlocher, A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201203154 · Cited by 211
Regulation of O -glycosylation through Golgi-to-ER relocation of initiation enzymes
Gill, D. J., Chia, J., Senewiratne, J., & Bard, F. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201003055 · Cited by 204
“Interestingly, Src regulates both cell adhesion and cell migration and has been associated with metastasis in vivo (Yeatman, 2004).”
BackgroundSong, L., Morris, M., Bagui, T., Lee, F. Y., Jove, R., & Haura, E. B. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4620 · Cited by 204
“cooperate with receptor tyrosine kinases to signal through downstream molecules, such as phosphatidylinositol 3-kinase (PI3K)/PTEN/Akt and STATs (6, 7, 9).”
BackgroundInfluentialThe dual kinase complex FAK-Src as a promising therapeutic target in cancer
Bolós, V. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s6909 · Cited by 202
“FAK and Src are not only critical modulators of signaling pathways mediated by TKRs and integrins, they also respond to stimuli from G protein-coupled receptors, cell–cell adhesion proteins (ie, cadherins) and steroid hormone receptors to control a variety of normal and oncogenic cellular responses such as cell surviv…”
InfluentialDynamic Protein Interaction Networks and New Structural Paradigms in Signaling
Csizmok, V., Follis, A. V., Kriwacki, R. W., & Forman-Kay, J. D. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00548 · Cited by 203
Reshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Vennin, C., Murphy, K. J., Morton, J. P., Cox, T. R., Pajic, M., & Timpson, P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.280 · Cited by 202
Zhong, Q., Zhou, B., Ann, D. K., Minoo, P., Liu, Y., Banfalvi, A., Krishnaveni, M. S., Dubourd, M., Demaio, L., Willis, B. C., et al. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0347oc · Cited by 200
“adhesion and cell migration through effects on both focal adhesions and adherens junctions (44), and specifically to induce tyrosine phosphorylation of b-catenin that leads to disruption of its association with E-cadherin, thereby disrupting cell–cell adhesion (45–47).”
BackgroundMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
de Melo Gagliato, D., Leonardo Fontes Jardim, D., Marchesi, M. S. P., & Hortobagyi, G. N. (2016) · Oncotarget · doi:10.18632/oncotarget.7043 · Cited by 198
“[67] Src has extensive interaction with transmembrane receptor tyrosine kinases (RTKs) at the cell membrane, such as HER1 and HER2.”
BackgroundInvading one step at a time: the role of invadopodia in tumor metastasis
Paz, H., Pathak, N., & Yang, J. (2014) · Oncogene · doi:10.1038/onc.2013.393 · Cited by 197
Haura, E. B., Tanvetyanon, T., Chiappori, A., Williams, C., Simon, G., Antonia, S., Gray, J., Litschauer, S., Tetteh, L., Neuger, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4029 · Cited by 194
“mors, including lung cancer, resulting from diverse mechanisms.(10,18-21) Small-molecule inhibitors of SFK have antitumor properties because they inhibit cell proliferation, survival, angiogenesis, and invasion.”
BackgroundFibronectin on circulating extracellular vesicles as a liquid biopsy to detect breast cancer
Moon, P.-G., Lee, J.-E., Cho, Y.-E., Lee, S. J., Chae, Y. S., Jung, J. H., Kim, I.-S., Park, H. Y., & Baek, M.-C. (2016) · Oncotarget · doi:10.18632/oncotarget.9561 · Cited by 193
Anoikis and EMT: Lethal "Liaisons" during Cancer Progression
Cao, Z., Livas, T., & Kyprianou, N. (2016) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2016016955 · Cited by 193
Fyn: A novel molecular target in cancer
Saito, Y. D., Jensen, A. R., Salgia, R., & Posadas, E. M. (2010) · Cancer · doi:10.1002/cncr.24879 · Cited by 192
“The role of Src in cancer is thoroughly reviewed in several publications and will not be reviewed here.(3) Instead, we will focus upon developments in understanding the role of Fyn in various biological processes such as cellular motility and morphogenesis.”
Steps in prostate cancer progression that lead to bone metastasis
Jin, J., Dayyani, F., & Gallick, G. E. (2011) · International Journal of Cancer · doi:10.1002/ijc.26024 · Cited by 185
“Specific mechanisms of Src activation have been detailed in many reviews.(76,80,81) In prostate cancer, Src is highly expressed in patient samples(82) and is associated with decreased patient survival and metastases.”
BackgroundSrc family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530
Chang, Y.-M., Bai, L., Liu, S., Yang, J. C., Kung, H.-J., & Evans, C. P. (2008) · Oncogene · doi:10.1038/onc.2008.250 · Cited by 185
The role of Src in prostate cancer
Fizazi, K. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm086 · Cited by 183
“Full activation requires the autophosphorylation of a tyrosine residue located within the catalytic domain (Y419 in the human protein) [2].”
BackgroundTargeting anoikis resistance in prostate cancer metastasis
Sakamoto, S., & Kyprianou, N. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.001 · Cited by 180
“A highly activated viral version of Src (v-Src) is the first oncogene to be discovered and responsible for the transforming properties of the oncogenic Rous sarcoma virus (Yeatman, 2004).”
BackgroundRho GTPases modulate malignant transformation of tumor cells
Orgaz, J. L., Herraiz, C., & Sanz-Moreno, V. (2014) · Small GTPases · doi:10.4161/sgtp.29019 · Cited by 177
“Its normal cellular counterpart, the product of the proto-oncogene cSrc, plays a key role in signal transduction processes by acting downstream from several cell surface receptors, such as EGFR, and it is amplified in a variety of cancers.(120) RhoA, Rac1, and Cdc42 play roles in cellular transformation mediated by Sr…”
BackgroundTargeting tumor cell motility to prevent metastasis
Palmer, T. D., Ashby, W. J., Lewis, J. D., & Zijlstra, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.04.008 · Cited by 173
“Discovered originally as a viral oncogene [55], Src is overexpressed and ectopically activated in a myriad of cancers [56].”
BackgroundVidal, M., Larson, D. E., & Cagan, R. L. (2006) · Developmental Cell · doi:10.1016/j.devcel.2005.11.007 · Cited by 173
Redox regulation of protein kinases
Truong, T. H., & Carroll, K. S. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.790873 · Cited by 169
“Abnormal expression or hyperactivation of c-Src is present in several human malignancies and has been linked to the development of human cancers (Yeatman, 2004).”
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors
Wu, Z., Chang, P.-C., Yang, J. C., Chu, C.-Y., Wang, L.-Y., Chen, N.-T., Ma, A.-H., Desai, S. J., Lo, S. H., Evans, C. P., et al. (2010) · Genes & Cancer · doi:10.1177/1947601909358324 · Cited by 166
“Although Src is rarely found as a mutated oncogene in human malignancies, elevated expression and activation of Src family kinases (SFKs) have been implicated in a variety of cancers, including glioblastoma, colon, lung, breast, and prostate cancers.(9) Among SFK members, Src(10,11) and Lyn(12) have been functionally…”
Anandamide inhibits adhesion and migration of breast cancer cells
Grimaldi, C., Pisanti, S., Laezza, C., Malfitano, A. M., Santoro, A., Vitale, M., Caruso, M. G., Notarnicola, M., Iacuzzo, I., Portella, G., et al. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.10.024 · Cited by 166
“Recruitment of Src to focal adhesions has been shown to be required for integrinmediated cell motility [5].”
BackgroundStructural and functional associations of apical junctions with cytoskeleton
Miyoshi, J., & Takai, Y. (2008) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2007.12.014 · Cited by 165
Potential therapeutic targets of epithelial–mesenchymal transition in melanoma
Pearlman, R. L., Montes de Oca, M. K., Pal, H. C., & Afaq, F. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.029 · Cited by 165
“Synthesis of MMP-2 and MMP-9 contributes to degradation of collagen and the basal lamina, increasing melanoma cell motility.”
Influentialvan Vliet, C., Bukczynska, P. E., Puryer, M. A., Sadek, C. M., Shields, B. J., Tremblay, M. L., & Tiganis, T. (2005) · Nature Immunology · doi:10.1038/ni1169 · Cited by 163
“SFKs are activated by autophosphorylation on their protein tyrosine kinase activation loops (Tyr418 in mammalian c-Src; Tyr416 in chicken c-Src; hereafter the mammalian numbering is used) and are inhibited by C-terminal tyrosyl phosphorylation (Tyr529 in mammalian c-Src; Tyr527 in chicken c-Src); mutation of the C-ter…”
BackgroundAutophagy as a modulator and target in prostate cancer
Farrow, J. M., Yang, J. C., & Evans, C. P. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.196 · Cited by 162
PRL3 Promotes Cell Invasion and Proliferation by Down-regulation of Csk Leading to Src Activation
Liang, F., Liang, J., Wang, W.-Q., Sun, J.-P., Udho, E., & Zhang, Z.-Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608940200 · Cited by 162
Syntenin mediates SRC function in exosomal cell-to-cell communication
Imjeti, N. S., Menck, K., Egea-Jimenez, A. L., Lecointre, C., Lembo, F., Bouguenina, H., Badache, A., Ghossoub, R., David, G., Roche, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713433114 · Cited by 161
“When SRC is activated by extracellular stimuli, the C-terminal tyrosine is dephosphorylated by protein tyrosine phosphatases, opening the protein and ultimately resulting in the autophosphorylation of tyrosine 416 (in chicken and 419 in human) in the kinase domain (3, 4).”
BackgroundManagement of breast cancer with targeted agents: importance of heterogenicity
Di Cosimo, S., & Baselga, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.234 · Cited by 161
Martin, G. S. (2004) · Oncogene · doi:10.1038/sj.onc.1208077 · Cited by 159
Chang, Q., Jorgensen, C., Pawson, T., & Hedley, D. W. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604676 · Cited by 158
“Although activation of STAT3 is linked to persistent activity of tyrosine kinases, including Src (Yeatman, 2004), STAT3 phosphorylation at Tyr 705, in response to cytokine stimulation, is generally mediated by Janus-activated kinase 1 (Ihle, 1995).”
BackgroundCurrent status of SRC inhibitors in solid tumor malignancies
Puls, L. N., Eadens, M., & Messersmith, W. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0408 · Cited by 158
Lu, K. V., Zhu, S., Cvrljevic, A., Huang, T. T., Sarkaria, S., Ahkavan, D., Dang, J., Dinca, E. B., Plaisier, S. B., Oderberg, I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0347 · Cited by 158
“The non-receptor tyrosine kinase Src was one of the first oncogenes identified, and the Src family of kinases (SFKs) collectively regulates a variety of cellular functions in many cancer types including proliferation, invasion, motility, survival, differentiation, and angiogenesis (9-11).”
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 164
A phase 2 trial of dasatinib in advanced melanoma
Kluger, H. M., Dudek, A. Z., McCann, C., Ritacco, J., Southard, N., Jilaveanu, L. B., Molinaro, A., & Sznol, M. (2011) · Cancer · doi:10.1002/cncr.25766 · Cited by 151
“C-src activation results in proliferation, invasion, angiogenesis and motility of cancer cells, and in many malignancies is active in advanced stage disease.(15) src-activated Stat3 signaling is necessary for growth and survival of melanoma cells.”
BackgroundBioorthogonal Chemical Activation of Kinases in Living Systems
Zhang, G., Li, J., Xie, R., Fan, X., Liu, Y., Zheng, S., Ge, Y., & Chen, P. R. (2016) · ACS Central Science · doi:10.1021/acscentsci.6b00024 · Cited by 164
“22 To track this phenotype in a dynamic manner, the bioorthogonal chemical activation was performed for speci fi c and rapid rescue of the oncogenic Src mutant.”
Developments of CRBN-based PROTACs as potential therapeutic agents
Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 162
Translational models of prostate cancer bone metastasis
Berish, R. B., Ali, A. N., Telmer, P. G., Ronald, J. A., & Leong, H. S. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0020-2 · Cited by 176
Taniguchi, K., Xia, L., Goldberg, H. J., Lee, K. W. K., Shah, A., Stavar, L., Masson, E., Momen, A., Shikatani, E. A., John, R., et al. (2013) · Diabetes · doi:10.2337/db12-1010 · Cited by 159
“Pertinent intracellular biochemical derangements that have been implicated include increases in advanced glycation end products (AGEs), polyol and hexosamine pathway flux, reactive oxygen species (ROS), and the activities of protein kinase C (PKC), extracellular signal–regulated kinase (ERK), p38, Akt, Jak, and rho ki…”
BackgroundInfluentialJallal, H., Valentino, M.-L., Chen, G., Boschelli, F., Ali, S., & Rabbani, S. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2027 · Cited by 148
HIF1α and HIF2α independently activate SRC to promote melanoma metastases
Hanna, S. C., Krishnan, B., Bailey, S. T., Moschos, S. J., Kuan, P.-F., Shimamura, T., Osborne, L. D., Siegel, M. B., Duncan, L. M., O’Brien, E. T., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66715 · Cited by 147
“PDGFR α , FAK, and SRC (Supplemental Table 2).”
InfluentialWang, S., Liu, S., Sun, H., Huang, T., Chan, C.-H., Yang, C., Yeh, H., Huang, Y., Chou, W., Lin, Y., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu218 · Cited by 156
Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc
Getlik, M., Grütter, C., Simard, J. R., Klüter, S., Rabiller, M., Rode, H. B., Robubi, A., & Rauh, D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9002928 · Cited by 159
Bai, Z., Hou, S., Zhang, S., Li, Z.-Y., & Zhou, P. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00673 · Cited by 146
Snail-induced claudin-11 prompts collective migration for tumour progression
Li, C.-F., Chen, J.-Y., Ho, Y.-H., Hsu, W., Wu, L.-C., Lan, H., Hsu, D. S., Tai, S., Chang, Y., & Yang, M. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0268-z · Cited by 147
Turro, E., Greene, D., Wijgaerts, A., Thys, C., Lentaigne, C., Bariana, T. K., Westbury, S. K., Kelly, A. M., Selleslag, D., Stephens, J. C., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7666 · Cited by 144
“Amino acid conservation across species and human SFKs. Fig.”
BackgroundInfluentialRexer, B. N., Ham, A.-J. L., Rinehart, C., Hill, S., de Matos Granja-Ingram, N., González-Angulo, A. M., Mills, G. B., Dave, B., Chang, J. C., Liebler, D. C., et al. (2011) · Oncogene · doi:10.1038/onc.2011.130 · Cited by 139
“This highlights the complex regulation of SFK expression and activation that also includes interaction with substrates, phosphatases, and subcellular localization (Finn 2008, Yeatman 2004).”
Modeling Human Cancers in Drosophila
Sonoshita, M., & Cagan, R. L. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.07.008 · Cited by 153
“In a variety of human cancers including melanoma, breast, and colorectal cancers, SRC family kinases (SFKs) are activated by various cues such as growth factors and cell–cell contact (Yeatman, 2004).”
BackgroundDirect cysteine sulfenylation drives activation of the Src kinase
Heppner, D. E., Dustin, C. M., Liao, C., Hristova, M., Veith, C., Little, A. C., Ahlers, B. A., White, S. L., Deng, B., Lam, Y.-W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06790-1 · Cited by 137
Metadata
- Authors
- Yeatman, T. J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J.
- ORCID
- Yeatman, Timothy J.
- Venue
- Nature Reviews Cancer
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 470-480
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2036988959
- Cited by
- 1,113
- References
- 115
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 20 · 2023: 43 · 2022: 43 · 2021: 46 · 2020: 44 · 2019: 39 · 2018: 49 · 2017: 44 · 2016: 69 · 2015: 56 · 2014: 72 · 2013: 79 · 2012: 73
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, non-receptor tyrosine kinase, cancer, metastasis, cell invasion, cell motility, cell proliferation, anticancer agents, tumor progression
- MeSH terms
- Antineoplastic Agents, Cell Division, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Phenotype, Gene Expression Regulation, Neoplastic, Genes, src, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.